A Randomized Pilot Study to Investigate the Safety and Immunologic Impact of Evolocumab When Given in Combination With Ipilimumab and Nivolumab in Treatment-Naïve Patients With Metastatic Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms TOP2101

Most Recent Events

18 Jul 2024 Planned End Date changed from 1 Dec 2025 to 1 Jun 2027.
18 Jul 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2025.
16 May 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight